Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

First Posted Date
2004-10-05
Last Posted Date
2012-07-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
46
Registration Number
NCT00002524
Locations
🇺🇸

MD Anderson Cancer Center Orlando, Orlando, Florida, United States

🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-09-16
Last Posted Date
2012-06-12
Lead Sponsor
Northwestern University
Registration Number
NCT00004172
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Sarcoma
First Posted Date
2004-09-02
Last Posted Date
2014-01-24
Lead Sponsor
Radiation Therapy Oncology Group
Registration Number
NCT00002791
Locations
🇺🇸

Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

🇺🇸

Harbor Hospital Center, Baltimore, Maryland, United States

and more 234 locations

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

First Posted Date
2004-08-26
Last Posted Date
2013-03-26
Lead Sponsor
Cancer Treatment Centers of America
Target Recruit Count
30
Registration Number
NCT00003406
Locations
🇺🇸

Midwestern Regional Medical Center, Zion, Illinois, United States

Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Phase 2
Completed
Conditions
Sarcoma
First Posted Date
2004-08-18
Last Posted Date
2013-06-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00003776
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

Phase 2
Conditions
Lung Cancer
First Posted Date
2004-08-13
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00003284
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-11
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
25
Registration Number
NCT00002865
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

First Posted Date
2004-08-09
Last Posted Date
2018-04-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
23
Registration Number
NCT00089544
Locations
🇺🇸

Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 1
Completed
Conditions
Lung Cancer
First Posted Date
2004-08-05
Last Posted Date
2013-04-12
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
55
Registration Number
NCT00004186
Locations
🇺🇸

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

First Posted Date
2004-07-12
Last Posted Date
2013-01-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
25
Registration Number
NCT00086944
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy